Clinical outcome of renal cancer patients who early interrupted immunotherapy due to serious immune-related adverse events. Meet-Uro 13 trial on behalf of the MeetUro investigators

Marco Stellato1*, Giuseppe Procopio2, Ugo De Giorgi3, Marco Maruzzo4, Davide Bimbatti4, Alessia Mennitto5, Andrea Sbrana6, Giandomenico Roviello7, Chiara Casadei3, Pierangela Sepe2, Sandro Pignata8 and Daniele Santini1

Abstract

Background: Severe immune-related Adverse Events (irAEs) develop in 10–27% of patients treated with Immune-Oncology (IO) [Powles (Lancet 391:748–757, 2018); Galsky (Lancet 395:1547–1557, 2020); Haanen (Ann Oncol 28:119–142, 2017)]. The aim of our study was to evaluate efficacy and clinical outcome of metastatic renal cell carcinoma (mRCC) patients who stopped Immune Checkpoint Inhibitors (ICIs) due to early Grade (G) 3-G4 irAEs.

Methods: We retrospectively collected data from 204 mRCC patients treated with ICIs in 6 Italian referral centers adhering to the Meet-Uro group, between February 2017 and January 2020. To properly weight the results, patients who did not report early G3–G4 toxicities have been included as control group.

Primary endpoint was to evaluate 6 months Progression Free Survival (PFS) after early treatment interruption for Grade (G) 3–4 toxicities compared to the control group. Secondary endpoints were to evaluate Time to treatment failure (TTF) and overall survival (OS) in both groups. All statistical analyses were performed using SPSS software (version 19.00, SPSS, Chicago).

Results: 18/204 (8.8%) patients had early treatment interruption for serious (G3-G4) irAEs. Early was defined as interruption of IO after only one or two administrations. Immune related nephritis and pancreatitis were the most common irAE that lead to treatment interruption. 6/18 patients received IO-IO combination whereas 12/18 patients antiPD1. In the study group, 12/18 (66.6%) were free from progression at 6 months since IO interruption, TTF was 1.6 months (95% CI 1.6–2.1), mPFS was 7.4 months (95% CI 3.16–11.6) and mOS was 15.5 months (5.1–25.8). In the control group 111/184 (60.3%) patients were free from progression at 6 months, TTF was 4.6 months (95% CI 3.5–5.6), mPFS was 4.6 months (95% CI 3.5–5.6) and mOS was 19.6 months (95% CI 15.1–24.0). In the overall population, mPFS was 5.0 months (95% CI 4.0–5.9) and mOS was 19.6 months (95% CI 15.1–24.0).

© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Immune-Oncology (IO), alone or in combination, changed the paradigm of treatment of metastatic renal cell carcinoma (mRCC) showing an improvement in Overall Survival (OS) and Progression Free Survival (PFS) compared to standard of care [1–3]. IO induces tumor death in a different way, compared to Vascular Endothelial Growth Factor Receptors (VEGFR)-Tyrosine Kinase Inhibitors (TKI), and, consequently, has different adverse events called immune related Adverse Events (irAEs).

Severe irAEs develop in 10–27% of patients treated with anti-Cytotoxic T-Lymphocyte Antigen (CTLA)-4, in amount 12–20% of patients treated with anti-programmed cell death (PD)-1 and 15–20% of patients treated with anti-programmed death-ligand (PD-L)-1 [4–7]. In mRCC G3-G4 irAE develop in 1.7–19% of patients treated with anti-PD1 [8] and 1.3–10.4% of patients treated with anti-PD1 + anti CTLA-4 [1].

Fathal irAE have been reported in almost 0.36% of patients treated with anti PD-1/PDL-1, 1.08% in those treated with anti-CTLA-4 and 1.23% of patients treated with combination [9]. IrAEs can involve kidney, lung, liver and skin but nervous system and osteoarticular manifestation have been described too [10].

According to recent reports, irAEs correlates with a better outcome [11]. IrAE can arise very early or after long time [11]. Long responders’ patients have been reported even after a short time to IO exposure.

Therefore, the aim of our study was to retrospectively evaluate the impact of early interruption of IO treatment, due to irAEs, on outcome of mRCC patients.

Methods
We retrospectively collected data of mRCC patients treated with IO in 6 Italian referral centers adhering to the Meet-Uro group, between February 2017 and January 2020.

Inclusion criteria were at least 18 years old at the time of enrollment, histological diagnosis of renal cell carcinoma and radiological diagnosis of metastatic disease.

Patients treated with IO as single agent or in combination were considered eligible.

Baseline characteristics were collected at the start of IO. Outcome data, including PFS, TTF, OS and toxicities, were collected too. Data included first line treatment, subsequent IO therapy and previous nephrectomy.

Results
Data from 204 mRCC patients were retrospectively collected from 6 referral centers. To properly weight the results, patients who did not report early G3-G4 toxicities have been included as control group. Characteristics of patients are described in Table 1. 18/204 (8.8%) patients had early treatment interruption for serious
(G3–G4) irAEs, 9/18 after 1 cycle. 10/18 had G3 toxicities whereas 8/18 G4 toxicities.

In the overall population, 190/204 patients received anti-PD1 whereas 14/204 patients were treated with antiCTLA4+antiPD1 combination. In the early discontinuation group, 6/18 patients received IO-IO combination whereas 12/18 patients antiPD1 ($p < 0.0001$) (Table 2). In the control group, 6 patients developed G2 irAEs after two month of IO treatment. Characteristic of patients who experienced early irAEs G3-G4 are described in Table 1 whereas Table 2 reports differences between group of patients who interrupted IO due to irAEs and patients who interrupted treatment due to progression.

In patients who developed early G3-G4 irAEs and then interrupted treatment, 12/18 (66.6%) patients were free from progression at 6 months from IO interruption whereas, in the control group, patients free from progression at 6 months, were 69/184 (37.5%) $p 0.1448$.

Immune related nephritis and pancreatitis were the most common irAEs that lead to early treatment

---

**Table 1** Characteristics of patients included in our study. Patients were grouped according to the reason for interruption of ICIs due to irAE or progressive disease

|                        | Interruption of IO |          |          |
|------------------------|--------------------|----------|----------|
|                        | G3-G4 irAE         | PD       |          |
|                        | 18                 | 186      |          |
| Sex                    | Male               | 10       | 98       |
|                        | Female             | 8        | 38       |
| Median age             | 66.0               | 60.9     |          |
| Site of disease        | Bone               | 9        | 44       |
|                        | Lung               | 18       | 73       |
|                        | Lymph nodes        | 12       | 69       |
|                        | Liver              | 6        | 19       |
|                        | Gland              | 4        | 28       |
| Synchronous metastatic disease | 10             | 85       |          |
| Metachronous metastatic disease | 8            | 101      |          |
| IMDC score             | Good               | 1        | 74       |
|                        | Intermediate       | 17       | 99       |
|                        | Poor               | 0        | 13       |
| IO                     | Single agent       | 12       | 178      |
|                        | IO–IO combo        | 6        | 8        |
| AID                    | Yes                | 2        | 3        |
|                        | Not                | 16       | 183      |
| ECOG PS                | 0                  | 12       | 96       |
|                        | 1                  | 5        | 72       |
|                        | 2                  | 1        | 18       |
| Line of treatment      | 1                  | 6        | 8        |
|                        | 2                  | 7        | 117      |
|                        | 3                  | 4        | 49       |
|                        | Further line       | 1        | 12       |

irAE: immune-related Adverse Events; G: grade; PD: progressive disease; IMDC score: International Metastatic RCC Database Consortium; AID: autoimmune disease; ECOG PS: Eastern Cooperative Oncology Group Performance Status; IO: Immune-Oncology

---

**Table 2** Difference between groups according to G3-G4 irAE interruption

|                        | No irAE interruption | irAE interruption | $p$     |
|------------------------|----------------------|-------------------|---------|
| PS ECOG                | 0                    | 94                | 12      | 0.182   |
|                        | 1                    | 72                | 5       | 0.0035  |
|                        | 2                    | 18                | 1       | 0.0018  |
| IMDC score             | Good                 | 55                | 1       | 0.027   |
|                        | Intermediate         | 116               | 17      | 0.347   |
|                        | Poor                 | 13                | 0       | 0.053   |
| Sex                    | M                    | 129               | 10      | 0.154   |
|                        | F                    | 51                | 8       | 0.413   |
| Synchronous metastatic disease | Y               | 85                | 10      | 0.448   |
|                        | N                    | 99                | 8       | 0.102   |
| Lung metastasis        | Y                    | 75                | 13      | 0.014   |
|                        | N                    | 61                | 5       | 0.067   |
| Liver metastasis       | Y                    | 19                | 3       | 0.759   |
|                        | N                    | 117               | 15      | 0.038   |
| Brain metastasis       | Y                    | 10                | 2       | 0.576   |
|                        | N                    | 126               | 16      | 0.237   |
| Gland metastasis       | Y                    | 28                | 2       | 0.340   |
|                        | N                    | 108               | 16      | 0.114   |
| Peritoneal metastasis  | Y                    | 8                 | 0       | 0.367   |
|                        | N                    | 176               | 18      | 0.0001  |
| IO                     | Anti-PD1             | 176               | 12      | < 0.0001|
|                        | Anti-PD1+antiCTLA4   | 8                 | 6       | 0.340   |

Y: YES; N: No; irAEs: immune-related Adverse Events; IO: Immune-Oncology; IMDC: score International Metastatic RCC Database Consortium; ECOG PS: Eastern Cooperative Oncology Group Performance Status; anti-PD1: anti programmed death 1; anti-CTLA4: anti-Cytotoxic T-Lymphocyte Antigen 4
interruption (Table 3). According to CTCAE version 5.0, nephritis was defined by increase in serum creatinine $> 3.0 \times$ baseline, managed initially by stopping nephrotoxic drugs (including over the counter medications), ruling out infection, urinary tract obstruction and correcting hypovolaemia whereas pancreatitis was defined as abdominal pain, pancreatic enzyme elevation and radiological findings of pancreatitis. IrAEs were reversible and were managed mainly with steroids, according to ESMO clinical practice guidelines [6].

In patients who interrupted treatment due to early irAEs, TTF was 1.6 months (95% CI 1.6–2.1), mPFS was 7.4 months (95% CI 3.16–11.6) and mOS was 15.5 months (5.1–25.8). In the control group, TTF was 4.6 months (95% CI 3.5–5.6), mPFS was 4.6 months (95% CI 3.5–5.6) and mOS was 19.6 months (95% CI 15.1–24.0).

In the overall population, median PFS was 5.0 months (95% CI 4.0–5.9) and median OS was 19.6 months (95% CI 15.1–24.0) whereas TTF was 4.1 months (95% CI 3.2–4.9). 125/204 patients were free from progression at 6 months.

12/18 patients did not receive further treatment after IO due to clinical deterioration.

Discussion
IrAEs contribute to mortality and morbidity in mRCC and represent a relevant issue for healthcare system. Symptoms and signs are often insidious and similar to cancer related symptoms so that irAEs represent a clinical challenge for physicians.

Biological biomarkers for irAEs are mostly unknown [12]. Baseline circulating Interleukin (IL)-17 was related to G3-G4 colitis [13] whereas Gowen et al. reported a different baseline profiling of antibodies in patients who developed irAEs [14].

In clinical practice, pre-existing organ insufficiency is supposed to be associated to higher risk to develop irAEs as well as pre-existing autoimmune disease (AID) [15]. In patients treated with ipilimumab, AID exacerbated in 27% of cases with 33% of irAE [16] whereas in patients treated with anti-PD-1, 38% had a flare of a preexisting AID with 10% of G3-G4 irAEs and a discontinuation rate of 4% [17–19]. In a larger cohort of patients, Tison et al. reported AID flare in 47% of cases and irAEs in 43% with a discontinuation rate of 21% [20]. Recrudescence of AID and irAEs are usually managed with corticosteroids. The use of immunosuppressive therapy at initiation of IO is associated to fewer irAEs compared to patients who did not receive corticosteroids.

In our real-world analysis, the incidence of early G3-G4 irAEs was almost 10–15%.

Outcomes here reported, demonstrate the efficacy of IO even after early interruption due to irAEs. Furthermore, after 6 months from treatment interruption, 66.6% of patients were free from progression demonstrating long-term benefit from IO. Indeed, G3-4 irAEs seem to be related to efficacy of IO even when treatment is early interrupted due to toxicities [11]. Differences in mPFS and mOS between the irAEs group and the control group was not analyzed due to the small sample size and the heterogeneity of patients in groups but the ones who experienced severe irAEs tend to a longer mPFS. Indeed, we reported longer mPFS in severe early irAEs group compared to mPFS reported in the pivotal trials of ICIs and other real-world experiences of IO in RCC. Median OS here reported was comparable to previous reports.

The hypothesis underling brilliant response after the onset of irAEs is that an exuberant activation of immune system against our self-tissues becomes an exuberant response against tumor tissue [11, 15]. Several modification have been seen in the immune system of patients treated with IO, which can explain long-term response [21]. In vitro, anti-CTLA4 is associated to an increase expansion and enhance effector function of memory CD8+ T cell, which can be related to long-term response [22]. Instead, it is uncertain if anti-PD1 increases CD8+ effector memory cells in cancer patients. Indeed, as reported in vitro, anti-PD1 enhance cytokine production in human T-cells and, in a T-reg suppression assay, it completely restored CD4+ T-responder cell proliferation and partially restored IFNγ production [23].

It is reasonable to suppose that in patients who develop early G3-4 irAEs, ICIs promote adapted states of hyper-responsiveness in immune cells, which promote anti-tumor immunity. This subgroup of patients

| Table 3 | IrAEs that lead to ICIs interruption |
|---------|-------------------------------------|
| **IrAE** | **N** |
| Miositis | 1 |
| Diabetes mellitus | 1 |
| Ipofisitis | 2 |
| Nefritis | 3 |
| Pneumonitis | 2 |
| Injection reaction | 2 |
| Colitis | 2 |
| Neuro toxicities | 2 |
| Pancreatitis | 3 |
| Arthritis | 1 |
| Ocular toxicities | 1 |
| Hemolytic anemia | 1 |
| Hepatitis | 2 |

N: number; IrAE: immune-related adverse events; ICIs: immune checkpoint inhibitors
might have a “hyper-immune system” and early G3–G4 irAEs could represent a predictive parameter for persistent adaptations in the immune system, which can persist and display memory-like features. Limits of our study are the small sample size, the retrospective collection of data and the lack of central radiological review. A prospective validation is needed to straighten these findings.

Conclusions
Pathogenesis and treatment of irAEs represent an interesting research field as it remains under debate. Interruption is often required after irAEs, with consequent doubts about treatment efficacy. Nevertheless, our study, with the limit of a retrospective collection, confirms that in mRCC patients, even after early interruption due to irAEs, IO maintain clinical and radiological efficacy.

Abbreviations
irAE: Immune-related Adverse Events; G, Grade; PD: Progressive disease; IMDC: International Metastatic RCC Database Consortium; AID: Autoimmune disease; ECOG PS: Eastern Cooperative Oncology Group Performance Status; IO: Immune-Oncology; OS: Overall Survival; PFS: Progression Free Survival; TTF: Time To Treatment Failure; mRCC: Metastatic Renal Cell Carcinoma; MSKCC: Memorial Sloane Kettering Cancer Center; RECIST: Response Evaluation Criteria in Solid Tumors; ICIs: Immune-Checkpoint Inhibitors; (CTLA)-4: Anti-Cytotoxic T-Lymphocyte Antigen; (PD)-1: Anti-Programmed Cell Death; (PD-L)-1: Anti-Programmed Death-Ligand.

Acknowledgements
Authors thank all MeetUro members for their contribution.

Authors’ contributions
All authors contributed equally to the paper. All authors read and approved the final manuscript.

Funding
None.

Availability of data and materials
Authors declare that data and material collected are available after properly request.

Declarations
Ethics approval and consent to participate
All participating centers received local ethics approval for data collections. All patients signed informed consent to participate to the study.

Consent for publication
Authors received consent for publication.

Competing interests
Sandro Pignata received honoraria from MSD AZ ROCHE Pfizer GS Clovis pharmamar and research funding MSD AZ ROCHE Pfizer. Ugo De Giorgi has served as consultant/advisory board member for Astellas, Bayer, BMS, Ipsen, Janssen, Merck, Pfizer and Sanofi; has received travel support from BMS, Ipsen, Janssen and Pfizer, and has received research funding from AstaZeneca, Roche and Sanofi (Inst.). All the other authors have no conflict of interest. Daniele Santini received honoraria from MSD, Pfizer, Astellas, Eisai, Janssen, Merck-Serono, Ipsen, Sanofi, BMS.

Author details
1 Department of Medical Oncology, Campus Bio-Medico University of Rome, Via Alvaro del Portillo 200, 00128 Rome, Italy. 2 Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. 3 IRCCS Istituto Raffaele Ricerca per lo Studio dei Tumori (IRST) Dino Amadori, Milano, Italy. 4 Medical Oncology Unit 1, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy. 5 Division of Oncology, University Hospital “Maggiore Della Carità”, Novara, Italy. 6 Department of Surgical, Medical and Molecular Pathology and Critical Area Medicine, University of Pisa, Pisa, Italy. 7 Department of Health Sciences, University of Florence, Florence, Italy. 8 Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione “G. Pascale”, Naples, Italy.

Received: 6 May 2021 Accepted: 23 July 2021
Published online: 03 August 2021

References
1. Motzer RJ, Rini BI, McDermott DF, Arén Frontera O, Hammers HJ, Carducci MA, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 2019;20(10):1370–85.
2. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–13.
3. Santini D, Stellato M, De Giorgi U, Pantano F, De Lisi D, Casadei C, et al. Clinical outcomes of metastatic renal carcinoma following disease progression to programmed death (PD)-1 or PD-L1 inhibitors (IO): a Meet-URO Group Real World Study (Meet-URO 7). Am J Clin Oncol. 2021;44(3):121–5.
4. Powles T, Durán I, van der Heijden MS, Lorigi Y, Vogelzang NJ, De Giorgi U, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMVigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2018;391(10122):748–57.
5. Galsky MD, Arija AA, Bamias A, Davis ID, De Santis M, Kikuchi E, et al. Atezolizumab with or without chemotherapy in metastatic urothelial carcinoma (IMVigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10236):1547–57.
6. Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(Supplement 4):119–42. https://doi.org/10.1093/annonc/mdx225.
7. Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol. 2017;8:49.
8. Motzer RJ, Escudier B, George S, Hammers HJ, Srinivas S, Tykodi SS, et al. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. Cancer. 2020;126(18):4156–67.
9. Wang DY, Salem J-E, Cohen JV, Chandra S, Menzer C, Ye F, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4(12):1721–B. https://doi.org/10.1001/jamaoncol.2018.3923.
10. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–68. https://doi.org/10.1056/NEJMra1703481.
11. Rogado J, Sánchez-Torres JM, Romero-Laorden N, Ballesteros AI, Pacheco-Baquero V, Ramos-Leví A, et al. Immune-related adverse events predict the therapeutic efficacy of anti–PD-1 antibodies in cancer patients. Eur J Cancer. 2019;109:21–7. https://doi.org/10.1016/j.ejca.2018.10.014.
12. Raimondi A, Sepe P, Zattarin E, Menntito A, Stellato M, Claps M, et al. Predictive biomarkers of response to immunotherapy in metastatic renal cell cancer. Front Oncol. 2020;10:1644.
13. Tarhini AA, Zahoor H, Lin Y, Malhotra U, Sander C, Butterfield LH, et al. Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J Immunother Cancer. 2015;3(1):39.
14. Nishino M, Sholl LM, Hatabu H, Ramaya NH, Hodi FS. Anti–PD-1–related pneumonitis during cancer immunotherapy. N Engl J Med. 2013;373(3):288–90.
15. Abdel-Wahab N, Shah M, Lopez-Olivo MA, Suarez-Almazor ME. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review. Ann Intern Med. 2018;168(2):121–30.
16. Johnson DB, Sullivan RI, Ott PA, Carlino MS, Khushalani NI, Ye F, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2016;2(2):234–40.
17. Brahmer JR, Drake CG, Wolner I, Powderly JD, Picus J, Sharman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19):3167–75.
18. Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, et al. Anti–PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol Off J Eur Soc Med Oncol. 2017;28(2):368–76.
19. Gutzmer R, Koop A, Meier F, Hassel JC, Terheyden P, Zimmer L, et al. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. Eur J Cancer. 2017;75:24–32.
20. Tison A, Quére G, Misery L, Funck-Brentano E, Danlos F-X, Routier E, et al. Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide, multicenter cohort study. Arthritis Rheumatol. 2019;71(12):2100–11.
21. Teracka S, Fujimoto D, Morimoto T, Kawachi H, Ito M, Sato Y, et al. Early immune-related adverse events and association with outcome in advanced non-small cell lung cancer patients treated with Nivolumab: a prospective cohort study. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2017;12(12):1798–803.
22. van der Vlist M, Kuball J, Radstake TRD, Meyaard L. Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us? Nat Rev Rheumatol. 2016;12(10):593–604. https://doi.org/10.1038/nrrheum.2016.131.
23. Pedicord VA, Montalvo W, Leiner IM, Allison JP. Single dose of anti–CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance. Proc Natl Acad Sci. 2011;108(1):266.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.